{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T21:49:16Z","timestamp":1792100956284,"version":"4.4.0"},"reference-count":173,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2013,1,23]],"date-time":"2013-01-23T00:00:00Z","timestamp":1358899200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Drugs Aging"],"published-print":{"date-parts":[[2013,3]]},"DOI":"10.1007\/s40266-013-0050-7","type":"journal-article","created":{"date-parts":[[2013,1,22]],"date-time":"2013-01-22T10:03:18Z","timestamp":1358848998000},"page":"137-153","source":"Crossref","is-referenced-by-count":31,"title":["Sj\u00f6gren\u2019s Syndrome in Older Patients"],"prefix":"10.1007","volume":"30","author":[{"given":"Rada V.","family":"Moerman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hendrika","family":"Bootsma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frans G. M.","family":"Kroese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arjan","family":"Vissink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,1,23]]},"reference":[{"issue":"12","key":"50_CR1","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1001\/archinte.164.12.1275","volume":"164","author":"SS Kassan","year":"2004","unstructured":"Kassan SS, Moutsopoulos HM. Clinical manifestations and early diagnosis of Sjogren syndrome. Arch Intern Med. 2004;164(12):1275\u201384.","journal-title":"Arch Intern Med"},{"issue":"6","key":"50_CR2","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1016\/j.berh.2007.09.001","volume":"21","author":"AG Tzioufas","year":"2007","unstructured":"Tzioufas AG, Voulgarelis M. Update on Sjogren\u2019s syndrome autoimmune epithelitis: from classification to increased neoplasias. Best Pract Res Clin Rheumatol. 2007;21(6):989\u20131010.","journal-title":"Best Pract Res Clin Rheumatol"},{"issue":"4","key":"50_CR3","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1097\/00005792-200207000-00003","volume":"81","author":"M Garcia-Carrasco","year":"2002","unstructured":"Garcia-Carrasco M, Ramos-Casals M, Rosas J, et al. Primary Sjogren syndrome: clinical and immunologic disease patterns in a cohort of 400 patients. Medicine (Baltimore). 2002;81(4):270\u201380.","journal-title":"Medicine (Baltimore)"},{"issue":"11","key":"50_CR4","doi-asserted-by":"crossref","first-page":"887","DOI":"10.2165\/00002512-200522110-00001","volume":"22","author":"I Al-Hashimi","year":"2005","unstructured":"Al-Hashimi I. Xerostomia secondary to Sjogren\u2019s syndrome in the elderly: recognition and management. Drugs Aging. 2005;22(11):887\u201399.","journal-title":"Drugs Aging"},{"issue":"1","key":"50_CR5","doi-asserted-by":"crossref","first-page":"19","DOI":"10.2165\/00002512-200825010-00003","volume":"25","author":"KP Ng","year":"2008","unstructured":"Ng KP, Isenberg DA. Sjogren\u2019s syndrome: diagnosis and therapeutic challenges in the elderly. Drugs Aging. 2008;25(1):19\u201333.","journal-title":"Drugs Aging"},{"issue":"3","key":"50_CR6","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1002\/art.20093","volume":"50","author":"MN Manoussakis","year":"2004","unstructured":"Manoussakis MN, Georgopoulou C, Zintzaras E, et al. Sjogren\u2019s syndrome associated with systemic lupus erythematosus: clinical and laboratory profiles and comparison with primary Sjogren\u2019s syndrome. Arthritis Rheum. 2004;50(3):882\u201391.","journal-title":"Arthritis Rheum"},{"issue":"9482","key":"50_CR7","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/S0140-6736(05)66990-5","volume":"366","author":"RI Fox","year":"2005","unstructured":"Fox RI. Sjogren\u2019s syndrome. Lancet. 2005;366(9482):321\u201331.","journal-title":"Lancet"},{"issue":"5","key":"50_CR8","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1097\/01.bor.0000172801.56744.c3","volume":"17","author":"A Hansen","year":"2005","unstructured":"Hansen A, Lipsky PE, Dorner T. Immunopathogenesis of primary Sjogren\u2019s syndrome: implications for disease management and therapy. Curr Opin Rheumatol. 2005;17(5):558\u201365.","journal-title":"Curr Opin Rheumatol"},{"issue":"9","key":"50_CR9","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1093\/rheumatology\/kep141","volume":"48","author":"JM Meijer","year":"2009","unstructured":"Meijer JM, Meiners PM, Huddleston Slater JJ, et al. Health-related quality of life, employment and disability in patients with Sjogren\u2019s syndrome. Rheumatology (Oxford). 2009;48(9):1077\u201382.","journal-title":"Rheumatology (Oxford)"},{"issue":"5","key":"50_CR10","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1191\/0961203303lu383ed","volume":"12","author":"M Ramos-Casals","year":"2003","unstructured":"Ramos-Casals M, Garcia-Carrasco M, Brito MP, et al. Autoimmunity and geriatrics: clinical significance of autoimmune manifestations in the elderly. Lupus. 2003;12(5):341\u201355.","journal-title":"Lupus"},{"issue":"2","key":"50_CR11","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.jbspin.2010.05.008","volume":"78","author":"C Botsios","year":"2011","unstructured":"Botsios C, Furlan A, Ostuni P, et al. Elderly onset of primary Sjogren\u2019s syndrome: clinical manifestations, serological features and oral\/ocular diagnostic tests. Comparison with adult and young onset of the disease in a cohort of 336 Italian patients. Joint Bone Spine. 2011;78(2):171\u20134.","journal-title":"Joint Bone Spine"},{"issue":"4","key":"50_CR12","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/0896-8411(89)90185-6","volume":"2","author":"LT Jacobsson","year":"1989","unstructured":"Jacobsson LT, Axell TE, Hansen BU, et al. Dry eyes or mouth\u2014an epidemiological study in Swedish adults, with special reference to primary Sjogren\u2019s syndrome. J Autoimmun. 1989;2(4):521\u20137.","journal-title":"J Autoimmun"},{"issue":"4","key":"50_CR13","first-page":"766","volume":"14","author":"RW Strickland","year":"1987","unstructured":"Strickland RW, Tesar JT, Berne BH, et al. The frequency of sicca syndrome in an elderly female population. J Rheumatol. 1987;14(4):766\u201371.","journal-title":"J Rheumatol"},{"issue":"12","key":"50_CR14","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1001\/archinte.159.12.1359","volume":"159","author":"OD Schein","year":"1999","unstructured":"Schein OD, Hochberg MC, Munoz B, et al. Dry eye and dry mouth in the elderly: a population-based assessment. Arch Intern Med. 1999;159(12):1359\u201363.","journal-title":"Arch Intern Med"},{"issue":"3","key":"50_CR15","first-page":"486","volume":"25","author":"MC Hochberg","year":"1998","unstructured":"Hochberg MC, Tielsch J, Munoz B, et al. Prevalence of symptoms of dry mouth and their relationship to saliva production in community dwelling elderly: the SEE project. Salisbury Eye Evaluation. J Rheumatol. 1998;25(3):486\u201391.","journal-title":"J Rheumatol"},{"issue":"7","key":"50_CR16","first-page":"38","volume":"64","author":"D Kim","year":"1998","unstructured":"Kim D, Uy C, Mandel L. Sialosis of unknown origin. N Y State Dent J. 1998;64(7):38\u201340.","journal-title":"N Y State Dent J"},{"issue":"3","key":"50_CR17","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1111\/j.1754-4505.1996.tb00842.x","volume":"16","author":"A Vissink","year":"1996","unstructured":"Vissink A, Spijkervet FK, Van Nieuw Amerongen A. Aging and saliva: a review of the literature. Spec Care Dent. 1996;16(3):95\u2013103.","journal-title":"Spec Care Dent"},{"issue":"1","key":"50_CR18","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.tripleo.2003.07.010","volume":"97","author":"SR Porter","year":"2004","unstructured":"Porter SR, Scully C, Hegarty AM. An update of the etiology and management of xerostomia. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2004;97(1):28\u201346.","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol Endod"},{"key":"50_CR19","doi-asserted-by":"crossref","unstructured":"Shiboski CH, Hodgson TA, Ship JA, et al. Management of salivary hypofunction during and after radiotherapy. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2007;103 Suppl:S66.e1\u201319.","DOI":"10.1016\/j.tripleo.2006.11.013"},{"issue":"3","key":"50_CR20","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1046\/j.1532-5415.2002.50123.x","volume":"50","author":"JA Ship","year":"2002","unstructured":"Ship JA, Pillemer SR, Baum BJ. Xerostomia and the geriatric patient. J Am Geriatr Soc. 2002;50(3):535\u201343.","journal-title":"J Am Geriatr Soc"},{"issue":"7","key":"50_CR21","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1177\/014556139907800707","volume":"78","author":"FC Astor","year":"1999","unstructured":"Astor FC, Hanft KL, Ciocon JO. Xerostomia: a prevalent condition in the elderly. Ear Nose Throat J. 1999;78(7):476\u20139.","journal-title":"Ear Nose Throat J"},{"issue":"9","key":"50_CR22","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1136\/ard.56.9.521","volume":"56","author":"UG Dafni","year":"1997","unstructured":"Dafni UG, Tzioufas AG, Staikos P, et al. Prevalence of Sjogren\u2019s syndrome in a closed rural community. Ann Rheum Dis. 1997;56(9):521\u20135.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"50_CR23","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1080\/03009740310004676","volume":"33","author":"SJ Bowman","year":"2004","unstructured":"Bowman SJ, Ibrahim GH, Holmes G, et al. Estimating the prevalence among Caucasian women of primary Sjogren\u2019s syndrome in two general practices in Birmingham, UK. Scand J Rheumatol. 2004;33(1):39\u201343.","journal-title":"Scand J Rheumatol"},{"issue":"6","key":"50_CR24","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/S0025-6196(11)62408-7","volume":"76","author":"SR Pillemer","year":"2001","unstructured":"Pillemer SR, Matteson EL, Jacobsson LT, et al. Incidence of physician-diagnosed primary Sjogren syndrome in residents of Olmsted County, Minnesota. Mayo Clin Proc. 2001;76(6):593\u20139.","journal-title":"Mayo Clin Proc"},{"issue":"3","key":"50_CR25","doi-asserted-by":"crossref","first-page":"221","DOI":"10.3109\/03009742.2010.536164","volume":"40","author":"LG Goransson","year":"2011","unstructured":"Goransson LG, Haldorsen K, Brun JG, et al. The point prevalence of clinically relevant primary Sjogren\u2019s syndrome in two Norwegian counties. Scand J Rheumatol. 2011;40(3):221\u20134.","journal-title":"Scand J Rheumatol"},{"issue":"1","key":"50_CR26","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1080\/03009740701678712","volume":"37","author":"AJ Haugen","year":"2008","unstructured":"Haugen AJ, Peen E, Hulten B, et al. Estimation of the prevalence of primary Sjogren\u2019s syndrome in two age-different community-based populations using two sets of classification criteria: the Hordaland Health Study. Scand J Rheumatol. 2008;37(1):30\u20134.","journal-title":"Scand J Rheumatol"},{"issue":"4","key":"50_CR27","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.semarthrit.2006.08.007","volume":"36","author":"M Ramos-Casals","year":"2007","unstructured":"Ramos-Casals M, Brito-Zeron P, Font J. The overlap of Sjogren\u2019s syndrome with other systemic autoimmune diseases. Semin Arthritis Rheum. 2007;36(4):246\u201355.","journal-title":"Semin Arthritis Rheum"},{"issue":"2","key":"50_CR28","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1136\/ard.55.2.116","volume":"55","author":"C Vitali","year":"1996","unstructured":"Vitali C, Bombardieri S, Moutsopoulos HM, et al. Assessment of the European classification criteria for Sjogren\u2019s syndrome in a series of clinically defined cases: results of a prospective multicentre study. The European Study Group on Diagnostic Criteria for Sjogren\u2019s Syndrome. Ann Rheum Dis. 1996;55(2):116\u201321.","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"50_CR29","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1093\/rheumatology\/37.10.1069","volume":"37","author":"E Thomas","year":"1998","unstructured":"Thomas E, Hay EM, Hajeer A, et al. Sjogren\u2019s syndrome: a community-based study of prevalence and impact. Br J Rheumatol. 1998;37(10):1069\u201376.","journal-title":"Br J Rheumatol"},{"issue":"3","key":"50_CR30","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1002\/art.1780360309","volume":"36","author":"C Vitali","year":"1993","unstructured":"Vitali C, Bombardieri S, Moutsopoulos HM, et al. Preliminary criteria for the classification of Sjogren\u2019s syndrome. Results of a prospective concerted action supported by the European Community. Arthritis Rheum. 1993;36(3):340\u20137.","journal-title":"Arthritis Rheum"},{"issue":"1","key":"50_CR31","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1191\/096120399678847353","volume":"8","author":"M Garcia-Carrasco","year":"1999","unstructured":"Garcia-Carrasco M, Cervera R, Rosas J, et al. Primary Sjogren\u2019s syndrome in the elderly: clinical and immunological characteristics. Lupus. 1999;8(1):20\u20133.","journal-title":"Lupus"},{"issue":"6","key":"50_CR32","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1136\/ard.61.6.554","volume":"61","author":"C Vitali","year":"2002","unstructured":"Vitali C, Bombardieri S, Jonsson R, et al. Classification criteria for Sjogren\u2019s syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis. 2002;61(6):554\u20138.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"50_CR33","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1186\/ar3234","volume":"13","author":"CG Kallenberg","year":"2011","unstructured":"Kallenberg CG, Vissink A, Kroese FG, et al. What have we learned from clinical trials in primary Sjogren\u2019s syndrome about pathogenesis? Arthritis Res Ther. 2011;13(1):205.","journal-title":"Arthritis Res Ther"},{"issue":"5","key":"50_CR34","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1097\/BOR.0b013e32833c36c5","volume":"22","author":"X Mariette","year":"2010","unstructured":"Mariette X, Gottenberg JE. Pathogenesis of Sjogren\u2019s syndrome and therapeutic consequences. Curr Opin Rheumatol. 2010;22(5):471\u20137.","journal-title":"Curr Opin Rheumatol"},{"issue":"9","key":"50_CR35","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1038\/nrrheum.2010.118","volume":"6","author":"M Voulgarelis","year":"2010","unstructured":"Voulgarelis M, Tzioufas AG. Pathogenetic mechanisms in the initiation and perpetuation of Sjogren\u2019s syndrome. Nat Rev Rheumatol. 2010;6(9):529\u201337.","journal-title":"Nat Rev Rheumatol"},{"issue":"8","key":"50_CR36","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1111\/j.1601-0825.2009.01582.x","volume":"15","author":"N Roescher","year":"2009","unstructured":"Roescher N, Tak PP, Illei GG. Cytokines in Sjogren\u2019s syndrome. Oral Dis. 2009;15(8):519\u201326.","journal-title":"Oral Dis"},{"issue":"10","key":"50_CR37","doi-asserted-by":"crossref","first-page":"2730","DOI":"10.1002\/art.10577","volume":"46","author":"N Ogawa","year":"2002","unstructured":"Ogawa N, Ping L, Zhenjun L, et al. Involvement of the interferon-gamma-induced T cell-attracting chemokines, interferon-gamma-inducible 10-kd protein (CXCL10) and monokine induced by interferon-gamma (CXCL9), in the salivary gland lesions of patients with Sjogren\u2019s syndrome. Arthritis Rheum. 2002;46(10):2730\u201341.","journal-title":"Arthritis Rheum"},{"issue":"8","key":"50_CR38","doi-asserted-by":"crossref","first-page":"2770","DOI":"10.1073\/pnas.0510837103","volume":"103","author":"JE Gottenberg","year":"2006","unstructured":"Gottenberg JE, Cagnard N, Lucchesi C, et al. Activation of IFN pathways and plasmacytoid dendritic cell recruitment in target organs of primary Sjogren\u2019s syndrome. Proc Natl Acad Sci USA. 2006;103(8):2770\u20135.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"8","key":"50_CR39","doi-asserted-by":"crossref","first-page":"2262","DOI":"10.1002\/art.27509","volume":"62","author":"V Devauchelle-Pensec","year":"2010","unstructured":"Devauchelle-Pensec V, Cagnard N, Pers JO, et al. Gene expression profile in the salivary glands of primary Sjogren\u2019s syndrome patients before and after treatment with rituximab. Arthritis Rheum. 2010;62(8):2262\u201371.","journal-title":"Arthritis Rheum"},{"issue":"3","key":"50_CR40","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.arr.2011.01.005","volume":"10","author":"AN Vallejo","year":"2011","unstructured":"Vallejo AN. Immunological hurdles of ageing: indispensable research of the human model. Ageing Res Rev. 2011;10(3):315\u20138.","journal-title":"Ageing Res Rev"},{"issue":"12","key":"50_CR41","first-page":"737","volume":"65","author":"X Mariette","year":"1998","unstructured":"Mariette X. The hepatitis C virus and systemic diseases. Rev Rhum Engl Ed. 1998;65(12):737\u201340.","journal-title":"Rev Rhum Engl Ed"},{"key":"50_CR42","doi-asserted-by":"crossref","unstructured":"Ramos-Casals M, Munoz S, Zeron PB. Hepatitis C virus and Sjogren\u2019s syndrome: trigger or mimic? Rheum Dis Clin N Am. 2008;34(4):869\u201384, vii.","DOI":"10.1016\/j.rdc.2008.08.007"},{"issue":"4","key":"50_CR43","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1186\/ar3361","volume":"13","author":"C Vitali","year":"2011","unstructured":"Vitali C. Immunopathologic differences of Sjogren\u2019s syndrome versus sicca syndrome in HCV and HIV infection. Arthritis Res Ther. 2011;13(4):233.","journal-title":"Arthritis Res Ther"},{"issue":"6","key":"50_CR44","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1080\/03009740802220075","volume":"37","author":"SR Hansen","year":"2008","unstructured":"Hansen SR, Hetta AK, Omdal R. Primary Sjogren\u2019s syndrome and sarcoidosis: coexistence more than by chance? Scand J Rheumatol. 2008;37(6):485\u20136.","journal-title":"Scand J Rheumatol"},{"issue":"2","key":"50_CR45","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1097\/01.md.0000121237.98962.1e","volume":"83","author":"M Ramos-Casals","year":"2004","unstructured":"Ramos-Casals M, Brito-Zeron P, Garcia-Carrasco M, et al. Sarcoidosis or Sjogren syndrome? Clues to defining mimicry or coexistence in 59 cases. Medicine (Baltimore). 2004;83(2):85\u201395.","journal-title":"Medicine (Baltimore)"},{"issue":"1","key":"50_CR46","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1136\/ard.2007.071563","volume":"67","author":"A Hartkamp","year":"2008","unstructured":"Hartkamp A, Geenen R, Godaert GL, et al. Effect of dehydroepiandrosterone administration on fatigue, well-being, and functioning in women with primary Sjogren syndrome: a randomised controlled trial. Ann Rheum Dis. 2008;67(1):91\u20137.","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"50_CR47","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1002\/art.1780360407","volume":"36","author":"H Foster","year":"1993","unstructured":"Foster H, Stephenson A, Walker D, et al. Linkage studies of HLA and primary Sjogren\u2019s syndrome in multicase families. Arthritis Rheum. 1993;36(4):473\u201384.","journal-title":"Arthritis Rheum"},{"issue":"8","key":"50_CR48","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.1002\/art.11103","volume":"48","author":"JE Gottenberg","year":"2003","unstructured":"Gottenberg JE, Busson M, Loiseau P, et al. In primary Sjogren\u2019s syndrome, HLA class II is associated exclusively with autoantibody production and spreading of the autoimmune response. Arthritis Rheum. 2003;48(8):2240\u20135.","journal-title":"Arthritis Rheum"},{"issue":"2\u20134","key":"50_CR49","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1080\/17402520600876911","volume":"13","author":"JM Anaya","year":"2006","unstructured":"Anaya JM, Delgado-Vega AM, Castiblanco J. Genetic basis of Sjogren\u2019s syndrome. How strong is the evidence? Clin Dev Immunol. 2006;13(2\u20134):209\u201322.","journal-title":"Clin Dev Immunol"},{"issue":"5","key":"50_CR50","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1007\/BF03324623","volume":"17","author":"RM Nagler","year":"2005","unstructured":"Nagler RM, Hershkovich O. Age-related changes in unstimulated salivary function and composition and its relations to medications and oral sensorial complaints. Aging Clin Exp Res. 2005;17(5):358\u201366.","journal-title":"Aging Clin Exp Res"},{"issue":"5","key":"50_CR51","doi-asserted-by":"crossref","first-page":"M285","DOI":"10.1093\/gerona\/50A.5.M285","volume":"50","author":"JA Ship","year":"1995","unstructured":"Ship JA, Nolan NE, Puckett SA. Longitudinal analysis of parotid and submandibular salivary flow rates in healthy, different-aged adults. J Gerontol A Biol Sci Med Sci. 1995;50(5):M285\u20139.","journal-title":"J Gerontol A Biol Sci Med Sci"},{"issue":"8729","key":"50_CR52","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1016\/0140-6736(90)93212-8","volume":"336","author":"JA Ship","year":"1990","unstructured":"Ship JA, Baum BJ. Is reduced salivary flow normal in old people? Lancet. 1990;336(8729):1507.","journal-title":"Lancet"},{"issue":"1","key":"50_CR53","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1159\/000021980","volume":"44","author":"CF Streckfus","year":"1998","unstructured":"Streckfus CF, Baur U, Brown LJ, et al. Effects of estrogen status and aging on salivary flow rates in healthy Caucasian women. Gerontology. 1998;44(1):32\u20139.","journal-title":"Gerontology"},{"issue":"5","key":"50_CR54","first-page":"421","volume":"10","author":"CK Yeh","year":"1998","unstructured":"Yeh CK, Johnson DA, Dodds MW. Impact of aging on human salivary gland function: a community-based study. Aging (Milano). 1998;10(5):421\u20138.","journal-title":"Aging (Milano)"},{"issue":"1","key":"50_CR55","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1034\/j.1600-0528.2000.280108.x","volume":"28","author":"M Bergdahl","year":"2000","unstructured":"Bergdahl M. Salivary flow and oral complaints in adult dental patients. Community Dent Oral Epidemiol. 2000;28(1):59\u201366.","journal-title":"Community Dent Oral Epidemiol"},{"issue":"6","key":"50_CR56","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/S0003-9969(98)00022-3","volume":"43","author":"M Wolff","year":"1998","unstructured":"Wolff M, Kleinberg I. Oral mucosal wetness in hypo- and normosalivators. Arch Oral Biol. 1998;43(6):455\u201362.","journal-title":"Arch Oral Biol"},{"key":"50_CR57","doi-asserted-by":"crossref","unstructured":"Dawes C. Physiological factors affecting salivary flow rate, oral sugar clearance, and the sensation of dry mouth in man. J Dent Res. 1987;66 Spec No:648\u201353.","DOI":"10.1177\/00220345870660S207"},{"issue":"4","key":"50_CR58","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/S0002-8177(87)54012-0","volume":"115","author":"PC Fox","year":"1987","unstructured":"Fox PC, Busch KA, Baum BJ. Subjective reports of xerostomia and objective measures of salivary gland performance. J Am Dent Assoc. 1987;115(4):581\u20134.","journal-title":"J Am Dent Assoc"},{"issue":"4","key":"50_CR59","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1034\/j.1601-0825.2003.03967.x","volume":"9","author":"C Scully","year":"2003","unstructured":"Scully C. Drug effects on salivary glands: dry mouth. Oral Dis. 2003;9(4):165\u201376.","journal-title":"Oral Dis"},{"issue":"4","key":"50_CR60","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1111\/j.1532-5415.1995.tb05815.x","volume":"43","author":"WJ Loesche","year":"1995","unstructured":"Loesche WJ, Bromberg J, Terpenning MS, et al. Xerostomia, xerogenic medications and food avoidances in selected geriatric groups. J Am Geriatr Soc. 1995;43(4):401\u20137.","journal-title":"J Am Geriatr Soc"},{"issue":"1","key":"50_CR61","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1111\/j.1741-2358.1997.00033.x","volume":"14","author":"LM Sreebny","year":"1997","unstructured":"Sreebny LM, Schwartz SS. A reference guide to drugs and dry mouth\u20142nd edition. Gerodontology. 1997;14(1):33\u201347.","journal-title":"Gerodontology"},{"issue":"2","key":"50_CR62","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/S0266-4356(97)90683-5","volume":"35","author":"EA Field","year":"1997","unstructured":"Field EA, Longman LP, Bucknall R, et al. The establishment of a xerostomia clinic: a prospective study. Br J Oral Maxillofac Surg. 1997;35(2):96\u2013103.","journal-title":"Br J Oral Maxillofac Surg"},{"issue":"1","key":"50_CR63","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1136\/ard.57.1.20","volume":"57","author":"EM Hay","year":"1998","unstructured":"Hay EM, Thomas E, Pal B, et al. Weak association between subjective symptoms or and objective testing for dry eyes and dry mouth: results from a population based study. Ann Rheum Dis. 1998;57(1):20\u20134.","journal-title":"Ann Rheum Dis"},{"key":"50_CR64","doi-asserted-by":"crossref","unstructured":"Pflugfelder SC. Tear dysfunction and the cornea: LXVIII Edward Jackson Memorial Lecture. Am J Ophthalmol. 2011;152(6):900\u2013909.e1.","DOI":"10.1016\/j.ajo.2011.08.023"},{"key":"50_CR65","unstructured":"Mikulicz J. Uber eine eigenartige symmetrische Erkankung der Thranen-und Mundspeicheldrusen. Beitrage zur Chirurgie, Festschrift gewidmet Theodor Billroth, Ferdinand Enke, Stuttgart; 1892. p. 610\u201330. http:\/\/archive.org\/stream\/beitrgezurchirur00stan#page\/n15\/mode\/2up . Accessed 23 Nov 2012."},{"key":"50_CR66","first-page":"376","volume":"32","author":"H Gougerot","year":"1925","unstructured":"Gougerot H. Insuffisance progressive et atrophie des glandes salivaires et muqueuses de la bouche, des confunctives (et parfois de muqueuses, nasale, laryngee, vulvaire). \u2018Serecheresse\u2019 de la bouche, des conjonctives, etc. Bulletin de la Societe francaise de dermatologie et de syphiligraphie. 1925;32:376.","journal-title":"Bulletin de la Societe francaise de dermatologie et de syphiligraphie"},{"key":"50_CR67","unstructured":"Sj\u00f6gren HSC. Zur Kenntnis der Keratoconfunctivitis sicca (Keratitis filiformis bei Hypofunktion der Tranendrusen). Acta Ophthalmol. 1933;Supplement II(1):151."},{"issue":"4","key":"50_CR68","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1002\/acr.21591","volume":"64","author":"SC Shiboski","year":"2012","unstructured":"Shiboski SC, Shiboski CH, Criswell L, et al. American College of Rheumatology classification criteria for Sjogren\u2019s syndrome: a data-driven, expert consensus approach in the Sjogren\u2019s International Collaborative Clinical Alliance Cohort. Arthritis Care Res (Hoboken). 2012;64(4):475\u201387.","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"50_CR69","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1080\/15027732.1986.12461371","volume":"61","author":"R Manthorpe","year":"1986","unstructured":"Manthorpe R, Oxholm P, Prause JU, et al. The Copenhagen criteria for Sjogren\u2019s syndrome. Scand J Rheumatol Suppl. 1986;61:19\u201321.","journal-title":"Scand J Rheumatol Suppl"},{"issue":"5","key":"50_CR70","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1002\/art.1780290501","volume":"29","author":"RI Fox","year":"1986","unstructured":"Fox RI, Robinson CA, Curd JG, et al. Sjogren\u2019s syndrome. Proposed criteria for classification. Arthritis Rheum. 1986;29(5):577\u201385.","journal-title":"Arthritis Rheum"},{"issue":"2","key":"50_CR71","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1093\/rheumatology\/kel266","volume":"46","author":"J Pijpe","year":"2007","unstructured":"Pijpe J, Kalk WW, van der Wal JE, et al. Parotid gland biopsy compared with labial biopsy in the diagnosis of patients with primary Sjogren\u2019s syndrome. Rheumatology (Oxford). 2007;46(2):335\u201341.","journal-title":"Rheumatology (Oxford)"},{"issue":"8","key":"50_CR72","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1136\/ard.2010.144782","volume":"70","author":"E Theander","year":"2011","unstructured":"Theander E, Vasaitis L, Baecklund E, et al. Lymphoid organisation in labial salivary gland biopsies is a possible predictor for the development of malignant lymphoma in primary Sjogren\u2019s syndrome. Ann Rheum Dis. 2011;70(8):1363\u20138.","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"50_CR73","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1001\/archotol.129.9.966","volume":"129","author":"A Vissink","year":"2003","unstructured":"Vissink A, Kalk WW, Mansour K, et al. Comparison of lacrimal and salivary gland involvement in Sjogren\u2019s syndrome. Arch Otolaryngol Head Neck Surg. 2003;129(9):966\u201371.","journal-title":"Arch Otolaryngol Head Neck Surg"},{"issue":"2","key":"50_CR74","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/S0002-9394(03)00203-4","volume":"136","author":"Y Ohashi","year":"2003","unstructured":"Ohashi Y, Ishida R, Kojima T, et al. Abnormal protein profiles in tears with dry eye syndrome. Am J Ophthalmol. 2003;136(2):291\u20139.","journal-title":"Am J Ophthalmol"},{"issue":"10","key":"50_CR75","doi-asserted-by":"crossref","first-page":"4309","DOI":"10.1167\/iovs.05-1504","volume":"47","author":"A Tomlinson","year":"2006","unstructured":"Tomlinson A, Khanal S, Ramaesh K, et al. Tear film osmolarity: determination of a referent for dry eye diagnosis. Investig Ophthalmol Vis Sci. 2006;47(10):4309\u201315.","journal-title":"Investig Ophthalmol Vis Sci"},{"key":"50_CR76","doi-asserted-by":"crossref","unstructured":"Lam H, Bleiden L, de Paiva CS, et al. Tear cytokine profiles in dysfunctional tear syndrome. Am J Ophthalmol. 2009;147(2):198\u2013205.e1.","DOI":"10.1016\/j.ajo.2008.08.032"},{"issue":"2","key":"50_CR77","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1167\/iovs.09-3425","volume":"51","author":"KC Yoon","year":"2010","unstructured":"Yoon KC, Park CS, You IC, et al. Expression of CXCL9, -10, -11, and CXCR3 in the tear film and ocular surface of patients with dry eye syndrome. Investig Ophthalmol Vis Sci. 2010;51(2):643\u201350.","journal-title":"Investig Ophthalmol Vis Sci"},{"issue":"1","key":"50_CR78","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1001\/archopht.1969.00990020012003","volume":"82","author":"OP Bijsterveld Van","year":"1969","unstructured":"Van Bijsterveld OP. Diagnostic tests in the Sicca syndrome. Arch Ophthalmol. 1969;82(1):10\u20134.","journal-title":"Arch Ophthalmol"},{"key":"50_CR79","doi-asserted-by":"crossref","unstructured":"Ship JA, Vissink A, Challacombe SJ. Use of prophylactic antifungals in the immunocompromised host. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2007;103 Suppl:S6.e1\u201314.","DOI":"10.1016\/j.tripleo.2006.11.003"},{"issue":"2","key":"50_CR80","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/S0188-4409(01)00371-X","volume":"33","author":"AE Soto-Rojas","year":"2002","unstructured":"Soto-Rojas AE, Kraus A. The oral side of Sjogren syndrome. Diagnosis and treatment. A review. Arch Med Res. 2002;33(2):95\u2013106.","journal-title":"Arch Med Res"},{"key":"50_CR81","doi-asserted-by":"crossref","unstructured":"Guggenheimer J, Moore PA. Xerostomia: etiology, recognition and treatment. J Am Dent Assoc. 2003;134(1):61\u20139 (quiz 118\u20139).","DOI":"10.14219\/jada.archive.2003.0018"},{"issue":"10","key":"50_CR82","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1034\/j.1600-0714.2003.00015.x","volume":"32","author":"T Tanida","year":"2003","unstructured":"Tanida T, Okamoto T, Okamoto A, et al. Decreased excretion of antimicrobial proteins and peptides in saliva of patients with oral candidiasis. J Oral Pathol Med. 2003;32(10):586\u201394.","journal-title":"J Oral Pathol Med"},{"issue":"1","key":"50_CR83","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1136\/ard.2006.052647","volume":"66","author":"J Pijpe","year":"2007","unstructured":"Pijpe J, Kalk WW, Bootsma H, et al. Progression of salivary gland dysfunction in patients with Sjogren\u2019s syndrome. Ann Rheum Dis. 2007;66(1):107\u201312.","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"50_CR84","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1136\/ard.61.2.137","volume":"61","author":"WW Kalk","year":"2002","unstructured":"Kalk WW, Vissink A, Stegenga B, et al. Sialometry and sialochemistry: a non-invasive approach for diagnosing Sjogren\u2019s syndrome. Ann Rheum Dis. 2002;61(2):137\u201344.","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"50_CR85","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1136\/ard.60.12.1110","volume":"60","author":"WW Kalk","year":"2001","unstructured":"Kalk WW, Vissink A, Spijkervet FK, et al. Sialometry and sialochemistry: diagnostic tools for Sjogren\u2019s syndrome. Ann Rheum Dis. 2001;60(12):1110\u20136.","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"50_CR86","first-page":"186","volume":"104","author":"A Vissink","year":"1997","unstructured":"Vissink A, Spijkervet FK, van Nieuw Amerongen A. Changes in secretion and composition of saliva with aging. Ned Tijdschr Tandheelkd. 1997;104(5):186\u20139.","journal-title":"Ned Tijdschr Tandheelkd"},{"issue":"6","key":"50_CR87","doi-asserted-by":"crossref","first-page":"888","DOI":"10.7326\/0003-4819-89-6-888","volume":"89","author":"SS Kassan","year":"1978","unstructured":"Kassan SS, Thomas TL, Moutsopoulos HM, et al. Increased risk of lymphoma in sicca syndrome. Ann Intern Med. 1978;89(6):888\u201392.","journal-title":"Ann Intern Med"},{"issue":"6","key":"50_CR88","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1136\/ard.2005.041186","volume":"65","author":"E Theander","year":"2006","unstructured":"Theander E, Henriksson G, Ljungberg O, et al. Lymphoma and other malignancies in primary Sjogren\u2019s syndrome: a cohort study on cancer incidence and lymphoma predictors. Ann Rheum Dis. 2006;65(6):796\u2013803.","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"50_CR89","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1002\/art.1780390508","volume":"39","author":"AG Tzioufas","year":"1996","unstructured":"Tzioufas AG, Boumba DS, Skopouli FN, et al. Mixed monoclonal cryoglobulinemia and monoclonal rheumatoid factor cross-reactive idiotypes as predictive factors for the development of lymphoma in primary Sjogren\u2019s syndrome. Arthritis Rheum. 1996;39(5):767\u201372.","journal-title":"Arthritis Rheum"},{"issue":"1","key":"50_CR90","first-page":"55","volume":"22","author":"E Bernacchi","year":"2004","unstructured":"Bernacchi E, Amato L, Parodi A, et al. Sjogren\u2019s syndrome: a retrospective review of the cutaneous features of 93 patients by the Italian Group of Immunodermatology. Clin Exp Rheumatol. 2004;22(1):55\u201362.","journal-title":"Clin Exp Rheumatol"},{"issue":"1","key":"50_CR91","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.jdermsci.2005.01.017","volume":"39","author":"E Bernacchi","year":"2005","unstructured":"Bernacchi E, Bianchi B, Amato L, et al. Xerosis in primary Sjogren syndrome: immunohistochemical and functional investigations. J Dermatol Sci. 2005;39(1):53\u20135.","journal-title":"J Dermatol Sci"},{"issue":"2","key":"50_CR92","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1046\/j.1365-2133.1997.18091892.x","volume":"137","author":"M Engelke","year":"1997","unstructured":"Engelke M, Jensen JM, Ekanayake-Mudiyanselage S, et al. Effects of xerosis and ageing on epidermal proliferation and differentiation. Br J Dermatol. 1997;137(2):219\u201325.","journal-title":"Br J Dermatol"},{"issue":"2","key":"50_CR93","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1097\/01.md.0000119465.24818.98","volume":"83","author":"M Ramos-Casals","year":"2004","unstructured":"Ramos-Casals M, Anaya JM, Garcia-Carrasco M, et al. Cutaneous vasculitis in primary Sjogren syndrome: classification and clinical significance of 52 patients. Medicine (Baltimore). 2004;83(2):96\u2013106.","journal-title":"Medicine (Baltimore)"},{"issue":"7","key":"50_CR94","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1007\/s00296-005-0599-5","volume":"25","author":"T Pirildar","year":"2005","unstructured":"Pirildar T, Tikiz C, Ozkaya S, et al. Endothelial dysfunction in patients with primary Sjogren\u2019s syndrome. Rheumatol Int. 2005;25(7):536\u20139.","journal-title":"Rheumatol Int"},{"issue":"9","key":"50_CR95","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1093\/rheumatology\/38.9.826","volume":"38","author":"M Tektonidou","year":"1999","unstructured":"Tektonidou M, Kaskani E, Skopouli FN, et al. Microvascular abnormalities in Sjogren\u2019s syndrome: nailfold capillaroscopy. Rheumatology (Oxford). 1999;38(9):826\u201330.","journal-title":"Rheumatology (Oxford)"},{"issue":"4","key":"50_CR96","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1007\/s001050051118","volume":"51","author":"A Kuhn","year":"2000","unstructured":"Kuhn A, Richter-Hintz D, Schuppe HC, et al. Annular erythema in Sjogren syndrome. A variant of cutaneous lupus erythematosus? Hautarzt. 2000;51(4):270\u20135.","journal-title":"Hautarzt"},{"issue":"6","key":"50_CR97","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1111\/j.1398-9995.2005.00761.x","volume":"60","author":"B Crestani","year":"2005","unstructured":"Crestani B. The respiratory system in connective tissue disorders. Allergy. 2005;60(6):715\u201334.","journal-title":"Allergy"},{"issue":"4","key":"50_CR98","first-page":"349","volume":"15","author":"P Mialon","year":"1997","unstructured":"Mialon P, Barthelemy L, Sebert P, et al. A longitudinal study of lung impairment in patients with primary Sjogren\u2019s syndrome. Clin Exp Rheumatol. 1997;15(4):349\u201354.","journal-title":"Clin Exp Rheumatol"},{"issue":"9","key":"50_CR99","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1741-7015-9-1","volume":"10","author":"SV Ramagopalan","year":"2011","unstructured":"Ramagopalan SV, Wotton CJ, Handel AE, et al. Risk of venous thromboembolism in people admitted to hospital with selected immune-mediated diseases: record-linkage study. BMC Med. 2011;10(9):1.","journal-title":"BMC Med"},{"issue":"5","key":"50_CR100","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1097\/MD.0b013e3181579781","volume":"86","author":"D Launay","year":"2007","unstructured":"Launay D, Hachulla E, Hatron PY, et al. Pulmonary arterial hypertension: a rare complication of primary Sjogren syndrome: report of 9 new cases and review of the literature. Medicine (Baltimore). 2007;86(5):299\u2013315.","journal-title":"Medicine (Baltimore)"},{"key":"50_CR101","doi-asserted-by":"crossref","unstructured":"Cain HC, Noble PW, Matthay RA. Pulmonary manifestations of Sjogren\u2019s syndrome. Clin Chest Med. 1998;19(4):687\u201399, viii.","DOI":"10.1016\/S0272-5231(05)70110-6"},{"issue":"5","key":"50_CR102","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1097\/WCO.0b013e32833de6ab","volume":"23","author":"J Chai","year":"2010","unstructured":"Chai J, Logigian EL. Neurological manifestations of primary Sjogren\u2019s syndrome. Curr Opin Neurol. 2010;23(5):509\u201313.","journal-title":"Curr Opin Neurol"},{"issue":"5","key":"50_CR103","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1097\/01.md.0000141099.53742.16","volume":"83","author":"S Delalande","year":"2004","unstructured":"Delalande S, de Seze J, Fauchais AL, et al. Neurologic manifestations in primary Sjogren syndrome: a study of 82 patients. Medicine (Baltimore). 2004;83(5):280\u201391.","journal-title":"Medicine (Baltimore)"},{"issue":"Pt 11","key":"50_CR104","doi-asserted-by":"crossref","first-page":"2518","DOI":"10.1093\/brain\/awh605","volume":"128","author":"K Mori","year":"2005","unstructured":"Mori K, Iijima M, Koike H, et al. The wide spectrum of clinical manifestations in Sjogren\u2019s syndrome-associated neuropathy. Brain. 2005;128(Pt 11):2518\u201334.","journal-title":"Brain"},{"issue":"4","key":"50_CR105","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1007\/s100670050105","volume":"18","author":"M Govoni","year":"1999","unstructured":"Govoni M, Bajocchi G, Rizzo N, et al. Neurological involvement in primary Sjogren\u2019s syndrome: clinical and instrumental evaluation in a cohort of Italian patients. Clin Rheumatol. 1999;18(4):299\u2013303.","journal-title":"Clin Rheumatol"},{"issue":"8","key":"50_CR106","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1136\/jnnp.57.8.983","volume":"57","author":"F Gemignani","year":"1994","unstructured":"Gemignani F, Marbini A, Pavesi G, et al. Peripheral neuropathy associated with primary Sjogren\u2019s syndrome. J Neurol Neurosurg Psychiatry. 1994;57(8):983\u20136.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"8","key":"50_CR107","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1093\/rheumatology\/keq111","volume":"49","author":"A Massara","year":"2010","unstructured":"Massara A, Bonazza S, Castellino G, et al. Central nervous system involvement in Sjogren\u2019s syndrome: unusual, but not unremarkable\u2014clinical, serological characteristics and outcomes in a large cohort of Italian patients. Rheumatology (Oxford). 2010;49(8):1540\u20139.","journal-title":"Rheumatology (Oxford)"},{"issue":"7","key":"50_CR108","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1007\/s004150170135","volume":"248","author":"C Lafitte","year":"2001","unstructured":"Lafitte C, Amoura Z, Cacoub P, et al. Neurological complications of primary Sjogren\u2019s syndrome. J Neurol. 2001;248(7):577\u201384.","journal-title":"J Neurol"},{"issue":"11","key":"50_CR109","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1093\/rheumatology\/38.11.1113","volume":"38","author":"M Pertovaara","year":"1999","unstructured":"Pertovaara M, Korpela M, Kouri T, et al. The occurrence of renal involvement in primary Sjogren\u2019s syndrome: a study of 78 patients. Rheumatology (Oxford). 1999;38(11):1113\u201320.","journal-title":"Rheumatology (Oxford)"},{"issue":"3","key":"50_CR110","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1007\/s10165-011-0538-0","volume":"22","author":"R Rajput","year":"2012","unstructured":"Rajput R, Sehgal A, Jain D, et al. Nephrocalcinosis: a rare presenting manifestation of primary Sjogren\u2019s syndrome. Mod Rheumatol. 2012;22(3):479\u201382.","journal-title":"Mod Rheumatol"},{"issue":"6","key":"50_CR111","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1007\/s00296-006-0257-6","volume":"27","author":"YS Yang","year":"2007","unstructured":"Yang YS, Peng CH, Sia SK, et al. Acquired hypophosphatemia osteomalacia associated with Fanconi\u2019s syndrome in Sjogren\u2019s syndrome. Rheumatol Int. 2007;27(6):593\u20137.","journal-title":"Rheumatol Int"},{"issue":"5","key":"50_CR112","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1093\/qjmed\/93.5.297","volume":"93","author":"K Aasarod","year":"2000","unstructured":"Aasarod K, Haga HJ, Berg KJ, et al. Renal involvement in primary Sjogren\u2019s syndrome. QJM. 2000;93(5):297\u2013304.","journal-title":"QJM"},{"issue":"4","key":"50_CR113","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1097\/00005792-200007000-00005","volume":"79","author":"A Goules","year":"2000","unstructured":"Goules A, Masouridi S, Tzioufas AG, et al. Clinically significant and biopsy-documented renal involvement in primary Sjogren syndrome. Medicine (Baltimore). 2000;79(4):241\u20139.","journal-title":"Medicine (Baltimore)"},{"issue":"4","key":"50_CR114","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1097\/MD.0b013e318181e6af","volume":"87","author":"M Ramos-Casals","year":"2008","unstructured":"Ramos-Casals M, Solans R, Rosas J, et al. Primary Sjogren syndrome in Spain: clinical and immunologic expression in 1010 patients. Medicine (Baltimore). 2008;87(4):210\u20139.","journal-title":"Medicine (Baltimore)"},{"issue":"6","key":"50_CR115","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1093\/rheumatology\/keq047","volume":"49","author":"AL Fauchais","year":"2010","unstructured":"Fauchais AL, Ouattara B, Gondran G, et al. Articular manifestations in primary Sjogren\u2019s syndrome: clinical significance and prognosis of 188 patients. Rheumatology (Oxford). 2010;49(6):1164\u201372.","journal-title":"Rheumatology (Oxford)"},{"issue":"7","key":"50_CR116","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1093\/rheumatology\/32.7.609","volume":"32","author":"CT Pease","year":"1993","unstructured":"Pease CT, Shattles W, Barrett NK, et al. The arthropathy of Sjogren\u2019s syndrome. Br J Rheumatol. 1993;32(7):609\u201313.","journal-title":"Br J Rheumatol"},{"issue":"5","key":"50_CR117","first-page":"685","volume":"9","author":"NA Pavlidis","year":"1982","unstructured":"Pavlidis NA, Karsh J, Moutsopoulos HM. The clinical picture of primary Sjogren\u2019s syndrome: a retrospective study. J Rheumatol. 1982;9(5):685\u201390.","journal-title":"J Rheumatol"},{"issue":"4","key":"50_CR118","first-page":"717","volume":"29","author":"B Lindvall","year":"2002","unstructured":"Lindvall B, Bengtsson A, Ernerudh J, et al. Subclinical myositis is common in primary Sjogren\u2019s syndrome and is not related to muscle pain. J Rheumatol. 2002;29(4):717\u201325.","journal-title":"J Rheumatol"},{"issue":"1","key":"50_CR119","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1097\/MCG.0b013e3182329d9c","volume":"46","author":"EC Ebert","year":"2012","unstructured":"Ebert EC. Gastrointestinal and hepatic manifestations of sjogren syndrome. J Clin Gastroenterol. 2012;46(1):25\u201330.","journal-title":"J Clin Gastroenterol"},{"issue":"1","key":"50_CR120","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1111\/j.1083-4389.2004.00197.x","volume":"9","author":"D Sorrentino","year":"2004","unstructured":"Sorrentino D, Faller G, DeVita S, et al. Helicobacter pylori associated antigastric autoantibodies: role in Sjogren\u2019s syndrome gastritis. Helicobacter. 2004;9(1):46\u201353.","journal-title":"Helicobacter"},{"issue":"1\u20132","key":"50_CR121","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.jaut.2011.11.005","volume":"39","author":"C Selmi","year":"2012","unstructured":"Selmi C, Meroni PL, Gershwin ME. Primary biliary cirrhosis and Sjogren\u2019s syndrome: autoimmune epithelitis. J Autoimmun. 2012;39(1\u20132):34\u201342.","journal-title":"J Autoimmun"},{"issue":"5","key":"50_CR122","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1093\/rheumatology\/keq009","volume":"49","author":"WF Ng","year":"2010","unstructured":"Ng WF, Bowman SJ. Primary Sjogren\u2019s syndrome: too dry and too tired. Rheumatology (Oxford). 2010;49(5):844\u201353.","journal-title":"Rheumatology (Oxford)"},{"issue":"8","key":"50_CR123","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1093\/rheumatology\/kei281","volume":"45","author":"MN Lazarus","year":"2006","unstructured":"Lazarus MN, Robinson D, Mak V, et al. Incidence of cancer in a cohort of patients with primary Sjogren\u2019s syndrome. Rheumatology (Oxford). 2006;45(8):1012\u20135.","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"50_CR124","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/MD.0b013e31824125e4","volume":"91","author":"M Voulgarelis","year":"2012","unstructured":"Voulgarelis M, Ziakas PD, Papageorgiou A, et al. Prognosis and outcome of non-Hodgkin lymphoma in primary sjogren syndrome. Medicine (Baltimore). 2012;91(1):1\u20139.","journal-title":"Medicine (Baltimore)"},{"issue":"10","key":"50_CR125","doi-asserted-by":"crossref","first-page":"2198","DOI":"10.3899\/jrheum.110077","volume":"38","author":"RP Pollard","year":"2011","unstructured":"Pollard RP, Pijpe J, Bootsma H, et al. Treatment of mucosa-associated lymphoid tissue lymphoma in Sjogren\u2019s syndrome: a retrospective clinical study. J Rheumatol. 2011;38(10):2198\u2013208.","journal-title":"J Rheumatol"},{"issue":"1","key":"50_CR126","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/S0002-9343(03)00257-2","volume":"115","author":"M Leppilahti","year":"2003","unstructured":"Leppilahti M, Tammela TL, Huhtala H, et al. Interstitial cystitis-like urinary symptoms among patients with Sjogren\u2019s syndrome: a population-based study in Finland. Am J Med. 2003;115(1):62\u20135.","journal-title":"Am J Med"},{"issue":"5","key":"50_CR127","first-page":"427","volume":"72","author":"JM Chalmers","year":"2006","unstructured":"Chalmers JM. Minimal intervention dentistry: part 1. Strategies for addressing the new caries challenge in older patients. J Can Dent Assoc. 2006;72(5):427\u201333.","journal-title":"J Can Dent Assoc"},{"issue":"9","key":"50_CR128","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1177\/00220345860650090301","volume":"65","author":"A Vissink","year":"1986","unstructured":"Vissink A, De Jong HP, Busscher HJ, et al. Wetting properties of human saliva and saliva substitutes. J Dent Res. 1986;65(9):1121\u20134.","journal-title":"J Dent Res"},{"issue":"6","key":"50_CR129","doi-asserted-by":"crossref","first-page":"719","DOI":"10.14219\/jada.archive.1998.0313","volume":"129","author":"PC Fox","year":"1998","unstructured":"Fox PC, Brennan M, Pillemer S, et al. Sjogren\u2019s syndrome: a model for dental care in the 21st century. J Am Dent Assoc. 1998;129(6):719\u201328.","journal-title":"J Am Dent Assoc"},{"issue":"6","key":"50_CR130","first-page":"383","volume":"29","author":"G Regelink","year":"1998","unstructured":"Regelink G, Vissink A, Reintsema H, et al. Efficacy of a synthetic polymer saliva substitute in reducing oral complaints of patients suffering from irradiation-induced xerostomia. Quintessence Int. 1998;29(6):383\u20138.","journal-title":"Quintessence Int"},{"issue":"2","key":"50_CR131","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1001\/archinte.159.2.174","volume":"159","author":"FB Vivino","year":"1999","unstructured":"Vivino FB, Al-Hashimi I, Khan Z, et al. Pilocarpine tablets for the treatment of dry mouth and dry eye symptoms in patients with Sjogren syndrome: a randomized, placebo-controlled, fixed-dose, multicenter trial. P92-01 Study Group. Arch Intern Med. 1999;159(2):174\u201381.","journal-title":"Arch Intern Med"},{"issue":"4","key":"50_CR132","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1097\/01.rhu.0000135553.08057.21","volume":"10","author":"AS Papas","year":"2004","unstructured":"Papas AS, Sherrer YS, Charney M, et al. Successful treatment of dry mouth and dry eye symptoms in Sjogren\u2019s syndrome patients with oral pilocarpine: a randomized, placebo-controlled, dose-adjustment study. J Clin Rheumatol. 2004;10(4):169\u201377.","journal-title":"J Clin Rheumatol"},{"issue":"3","key":"50_CR133","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1002\/art.510","volume":"46","author":"D Petrone","year":"2002","unstructured":"Petrone D, Condemi JJ, Fife R, et al. A double-blind, randomized, placebo-controlled study of cevimeline in Sjogren\u2019s syndrome patients with xerostomia and keratoconjunctivitis sicca. Arthritis Rheum. 2002;46(3):748\u201354.","journal-title":"Arthritis Rheum"},{"issue":"11","key":"50_CR134","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1001\/archinte.162.11.1293","volume":"162","author":"RS Fife","year":"2002","unstructured":"Fife RS, Chase WF, Dore RK, et al. Cevimeline for the treatment of xerostomia in patients with Sjogren syndrome: a randomized trial. Arch Intern Med. 2002;162(11):1293\u2013300.","journal-title":"Arch Intern Med"},{"issue":"4","key":"50_CR135","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1002\/art.11199","volume":"49","author":"MJ Cummins","year":"2003","unstructured":"Cummins MJ, Papas A, Kammer GM, et al. Treatment of primary Sjogren\u2019s syndrome with low-dose human interferon alfa administered by the oromucosal route: combined phase III results. Arthritis Rheum. 2003;49(4):585\u201393.","journal-title":"Arthritis Rheum"},{"issue":"1","key":"50_CR136","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1067\/moe.2003.30","volume":"95","author":"AV Khurshudian","year":"2003","unstructured":"Khurshudian AV. A pilot study to test the efficacy of oral administration of interferon-alpha lozenges to patients with Sjogren\u2019s syndrome. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2003;95(1):38\u201344.","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol Endod"},{"issue":"5","key":"50_CR137","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1016\/S0161-6420(00)00035-X","volume":"107","author":"D Stevenson","year":"2000","unstructured":"Stevenson D, Tauber J, Reis BL. Efficacy and safety of cyclosporin A ophthalmic emulsion in the treatment of moderate-to-severe dry eye disease: a dose-ranging, randomized trial. The Cyclosporin A Phase 2 Study Group. Ophthalmology. 2000;107(5):967\u201374.","journal-title":"Ophthalmology"},{"issue":"3","key":"50_CR138","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/S0889-857X(21)00317-3","volume":"18","author":"TE Daniels","year":"1992","unstructured":"Daniels TE, Fox PC. Salivary and oral components of Sjogren\u2019s syndrome. Rheum Dis Clin N Am. 1992;18(3):571\u201389.","journal-title":"Rheum Dis Clin N Am"},{"issue":"3","key":"50_CR139","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1136\/ard.2006.057919","volume":"66","author":"R Seror","year":"2007","unstructured":"Seror R, Sordet C, Guillevin L, et al. Tolerance and efficacy of rituximab and changes in serum B cell biomarkers in patients with systemic complications of primary Sjogren\u2019s syndrome. Ann Rheum Dis. 2007;66(3):351\u20137.","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"50_CR140","doi-asserted-by":"crossref","first-page":"2740","DOI":"10.1002\/art.21260","volume":"52","author":"J Pijpe","year":"2005","unstructured":"Pijpe J, van Imhoff GW, Spijkervet FK, et al. Rituximab treatment in patients with primary Sjogren\u2019s syndrome: an open-label phase II study. Arthritis Rheum. 2005;52(9):2740\u201350.","journal-title":"Arthritis Rheum"},{"issue":"6","key":"50_CR141","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1136\/ard.2004.029694","volume":"64","author":"JE Gottenberg","year":"2005","unstructured":"Gottenberg JE, Guillevin L, Lambotte O, et al. Tolerance and short term efficacy of rituximab in 43 patients with systemic autoimmune diseases. Ann Rheum Dis. 2005;64(6):913\u201320.","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"50_CR142","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1002\/art.22536","volume":"57","author":"V Devauchelle-Pensec","year":"2007","unstructured":"Devauchelle-Pensec V, Pennec Y, Morvan J, et al. Improvement of Sjogren\u2019s syndrome after two infusions of rituximab (anti-CD20). Arthritis Rheum. 2007;57(2):310\u20137.","journal-title":"Arthritis Rheum"},{"issue":"11","key":"50_CR143","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1136\/ard.2007.083865","volume":"67","author":"S Dass","year":"2008","unstructured":"Dass S, Bowman SJ, Vital EM, et al. Reduction of fatigue in Sjogren syndrome with rituximab: results of a randomised, double-blind, placebo-controlled pilot study. Ann Rheum Dis. 2008;67(11):1541\u20134.","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"50_CR144","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1002\/art.27314","volume":"62","author":"JM Meijer","year":"2010","unstructured":"Meijer JM, Meiners PM, Vissink A, et al. Effectiveness of rituximab treatment in primary Sjogren\u2019s syndrome: a randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2010;62(4):960\u20138.","journal-title":"Arthritis Rheum"},{"issue":"4","key":"50_CR145","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1093\/rheumatology\/keh506","volume":"44","author":"LJ Dawson","year":"2005","unstructured":"Dawson LJ, Caulfield VL, Stanbury JB, et al. Hydroxychloroquine therapy in patients with primary Sjogren\u2019s syndrome may improve salivary gland hypofunction by inhibition of glandular cholinesterase. Rheumatology (Oxford). 2005;44(4):449\u201355.","journal-title":"Rheumatology (Oxford)"},{"issue":"5","key":"50_CR146","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1136\/ard.52.5.360","volume":"52","author":"AA Kruize","year":"1993","unstructured":"Kruize AA, Hene RJ, Kallenberg CG, et al. Hydroxychloroquine treatment for primary Sjogren\u2019s syndrome: a two year double blind crossover trial. Ann Rheum Dis. 1993;52(5):360\u20134.","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"50_CR147","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/S0181-5512(04)96119-0","volume":"27","author":"F Rigaudiere","year":"2004","unstructured":"Rigaudiere F, Ingster-Moati I, Hache JC, et al. Up-dated ophthalmological screening and follow-up management for long-term antimalarial treatment. J Fr Ophtalmol. 2004;27(2):191\u20139.","journal-title":"J Fr Ophtalmol"},{"issue":"4","key":"50_CR148","first-page":"709","volume":"33","author":"J Seze de","year":"2006","unstructured":"de Seze J, Delalande S, Fauchais AL, et al. Myelopathies secondary to Sjogren\u2019s syndrome: treatment with monthly intravenous cyclophosphamide associated with corticosteroids. J Rheumatol. 2006;33(4):709\u201311.","journal-title":"J Rheumatol"},{"issue":"2","key":"50_CR149","first-page":"149","volume":"11","author":"PC Fox","year":"1993","unstructured":"Fox PC, Datiles M, Atkinson JC, et al. Prednisone and piroxicam for treatment of primary Sjogren\u2019s syndrome. Clin Exp Rheumatol. 1993;11(2):149\u201356.","journal-title":"Clin Exp Rheumatol"},{"issue":"5","key":"50_CR150","first-page":"555","volume":"14","author":"FN Skopouli","year":"1996","unstructured":"Skopouli FN, Jagiello P, Tsifetaki N, et al. Methotrexate in primary Sjogren\u2019s syndrome. Clin Exp Rheumatol. 1996;14(5):555\u20138.","journal-title":"Clin Exp Rheumatol"},{"key":"50_CR151","unstructured":"The effect of age and renal function on the efficacy and toxicity of methotrexate in rheumatoid arthritis. Rheumatoid Arthritis Clinical Trial Archive Group. J Rheumatol. 1995;22(2):218\u201323."},{"issue":"5","key":"50_CR152","first-page":"896","volume":"25","author":"EJ Price","year":"1998","unstructured":"Price EJ, Rigby SP, Clancy U, et al. A double blind placebo controlled trial of azathioprine in the treatment of primary Sjogren\u2019s syndrome. J Rheumatol. 1998;25(5):896\u20139.","journal-title":"J Rheumatol"},{"issue":"5","key":"50_CR153","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.semarthrit.2007.06.002","volume":"37","author":"A Thanou-Stavraki","year":"2008","unstructured":"Thanou-Stavraki A, James JA. Primary Sjogren\u2019s syndrome: current and prospective therapies. Semin Arthritis Rheum. 2008;37(5):273\u201392.","journal-title":"Semin Arthritis Rheum"},{"issue":"8","key":"50_CR154","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1136\/ard.2006.060905","volume":"66","author":"JM Woerkom van","year":"2007","unstructured":"van Woerkom JM, Kruize AA, Geenen R, et al. Safety and efficacy of leflunomide in primary Sjogren\u2019s syndrome: a phase II pilot study. Ann Rheum Dis. 2007;66(8):1026\u201332.","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"50_CR155","doi-asserted-by":"crossref","first-page":"395","DOI":"10.2165\/00002512-200926050-00003","volume":"26","author":"S Alivernini","year":"2009","unstructured":"Alivernini S, Mazzotta D, Zoli A, et al. Leflunomide treatment in elderly patients with rheumatoid or psoriatic arthritis: retrospective analysis of safety and adherence to treatment. Drugs Aging. 2009;26(5):395\u2013402.","journal-title":"Drugs Aging"},{"issue":"4","key":"50_CR156","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1002\/art.20146","volume":"50","author":"X Mariette","year":"2004","unstructured":"Mariette X, Ravaud P, Steinfeld S, et al. Inefficacy of infliximab in primary Sjogren\u2019s syndrome: results of the randomized, controlled Trial of Remicade in Primary Sjogren\u2019s Syndrome (TRIPSS). Arthritis Rheum. 2004;50(4):1270\u20136.","journal-title":"Arthritis Rheum"},{"issue":"1","key":"50_CR157","first-page":"96","volume":"31","author":"MM Zandbelt","year":"2004","unstructured":"Zandbelt MM, de Wilde P, van Damme P, et al. Etanercept in the treatment of patients with primary Sjogren\u2019s syndrome: a pilot study. J Rheumatol. 2004;31(1):96\u2013101.","journal-title":"J Rheumatol"},{"issue":"11","key":"50_CR158","doi-asserted-by":"crossref","first-page":"3251","DOI":"10.1002\/art.24903","volume":"60","author":"J Pijpe","year":"2009","unstructured":"Pijpe J, Meijer JM, Bootsma H, et al. Clinical and histologic evidence of salivary gland restoration supports the efficacy of rituximab treatment in Sjogren\u2019s syndrome. Arthritis Rheum. 2009;60(11):3251\u20136.","journal-title":"Arthritis Rheum"},{"issue":"2","key":"50_CR159","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1136\/ard.2008.092601","volume":"68","author":"JM Meijer","year":"2009","unstructured":"Meijer JM, Pijpe J, Vissink A, et al. Treatment of primary Sjogren syndrome with rituximab: extended follow-up, safety and efficacy of retreatment. Ann Rheum Dis. 2009;68(2):284\u20135.","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"50_CR160","doi-asserted-by":"crossref","first-page":"R129","DOI":"10.1186\/ar2018","volume":"8","author":"SD Steinfeld","year":"2006","unstructured":"Steinfeld SD, Tant L, Burmester GR, et al. Epratuzumab (humanised anti-CD22 antibody) in primary Sjogren\u2019s syndrome: an open-label phase I\/II study. Arthritis Res Ther. 2006;8(4):R129.","journal-title":"Arthritis Res Ther"},{"issue":"8","key":"50_CR161","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1002\/1529-0131(199908)42:8<1765::AID-ANR28>3.0.CO;2-V","volume":"42","author":"M Voulgarelis","year":"1999","unstructured":"Voulgarelis M, Dafni UG, Isenberg DA, et al. Malignant lymphoma in primary Sjogren\u2019s syndrome: a multicenter, retrospective, clinical study by the European Concerted Action on Sjogren\u2019s Syndrome. Arthritis Rheum. 1999;42(8):1765\u201372.","journal-title":"Arthritis Rheum"},{"issue":"12","key":"50_CR162","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1093\/rheumatology\/kem280","volume":"46","author":"SJ Bowman","year":"2007","unstructured":"Bowman SJ, Sutcliffe N, Isenberg DA, et al. Sjogren\u2019s Systemic Clinical Activity Index (SCAI)\u2014a systemic disease activity measure for use in clinical trials in primary Sjogren\u2019s syndrome. Rheumatology (Oxford). 2007;46(12):1845\u201351.","journal-title":"Rheumatology (Oxford)"},{"issue":"7","key":"50_CR163","doi-asserted-by":"crossref","first-page":"2223","DOI":"10.1002\/art.22658","volume":"56","author":"C Vitali","year":"2007","unstructured":"Vitali C, Palombi G, Baldini C, et al. Sjogren\u2019s Syndrome Disease Damage Index and disease activity index: scoring systems for the assessment of disease damage and disease activity in Sjogren\u2019s syndrome, derived from an analysis of a cohort of Italian patients. Arthritis Rheum. 2007;56(7):2223\u201331.","journal-title":"Arthritis Rheum"},{"issue":"8","key":"50_CR164","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1136\/annrheumdis-2011-200460","volume":"71","author":"PM Meiners","year":"2012","unstructured":"Meiners PM, Arends S, Brouwer E, et al. Responsiveness of disease activity indices ESSPRI and ESSDAI in patients with primary Sjogren\u2019s syndrome treated with rituximab. Ann Rheum Dis. 2012;71(8):1297\u2013302.","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"50_CR165","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1001\/jama.2010.1014","volume":"304","author":"M Ramos-Casals","year":"2010","unstructured":"Ramos-Casals M, Tzioufas AG, Stone JH, et al. Treatment of primary Sjogren syndrome: a systematic review. JAMA. 2010;304(4):452\u201360.","journal-title":"JAMA"},{"issue":"4","key":"50_CR166","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1002\/acr.20173","volume":"62","author":"R Seror","year":"2010","unstructured":"Seror R, Mariette X, Bowman S, et al. Accurate detection of changes in disease activity in primary Sjogren\u2019s syndrome by the European League Against Rheumatism Sjogren\u2019s Syndrome Disease Activity Index. Arthritis Care Res (Hoboken). 2010;62(4):551\u20138.","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"6","key":"50_CR167","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1136\/ard.2009.110619","volume":"69","author":"R Seror","year":"2010","unstructured":"Seror R, Ravaud P, Bowman SJ, et al. EULAR Sjogren\u2019s syndrome disease activity index: development of a consensus systemic disease activity index for primary Sjogren\u2019s syndrome. Ann Rheum Dis. 2010;69(6):1103\u20139.","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"50_CR168","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.1002\/art.21205","volume":"52","author":"JO Pers","year":"2005","unstructured":"Pers JO, d\u2019Arbonneau F, Devauchelle-Pensec V, et al. Is periodontal disease mediated by salivary BAFF in Sjogren\u2019s syndrome? Arthritis Rheum. 2005;52(8):2411\u20134.","journal-title":"Arthritis Rheum"},{"issue":"6","key":"50_CR169","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1007\/s10875-004-6240-7","volume":"24","author":"P Szodoray","year":"2004","unstructured":"Szodoray P, Jellestad S, Alex P, et al. Programmed cell death of peripheral blood B cells determined by laser scanning cytometry in Sjogren\u2019s syndrome with a special emphasis on BAFF. J Clin Immunol. 2004;24(6):600\u201311.","journal-title":"J Clin Immunol"},{"issue":"8","key":"50_CR170","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1002\/pmic.201000206","volume":"11","author":"S Hu","year":"2011","unstructured":"Hu S, Vissink A, Arellano M, et al. Identification of autoantibody biomarkers for primary Sjogren\u2019s syndrome using protein microarrays. Proteomics. 2011;11(8):1499\u2013507.","journal-title":"Proteomics"},{"issue":"11","key":"50_CR171","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1002\/acr.20289","volume":"62","author":"S Hu","year":"2010","unstructured":"Hu S, Gao K, Pollard R, et al. Preclinical validation of salivary biomarkers for primary Sjogren\u2019s syndrome. Arthritis Care Res (Hoboken). 2010;62(11):1633\u20138.","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"2","key":"50_CR172","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1111\/j.1600-0722.2007.00432.x","volume":"115","author":"I Berg van den","year":"2007","unstructured":"van den Berg I, Pijpe J, Vissink A. Salivary gland parameters and clinical data related to the underlying disorder in patients with persisting xerostomia. Eur J Oral Sci. 2007;115(2):97\u2013102.","journal-title":"Eur J Oral Sci"},{"key":"50_CR173","doi-asserted-by":"crossref","unstructured":"Bootsma H, Spijkervet FK, Kroese FG, et al. Towards new classification criteria for Sj\u00f6gren\u2019s syndrome? Arthritis Rheum. 2013;65(1):21\u201323.","DOI":"10.1002\/art.37701"}],"container-title":["Drugs &amp; Aging"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40266-013-0050-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40266-013-0050-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40266-013-0050-7","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,29]],"date-time":"2025-04-29T18:04:36Z","timestamp":1745949876000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40266-013-0050-7"}},"subtitle":["Aetiology, Diagnosis and Management"],"short-title":[],"issued":{"date-parts":[[2013,1,23]]},"references-count":173,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2013,3]]}},"alternative-id":["50"],"URL":"https:\/\/doi.org\/10.1007\/s40266-013-0050-7","relation":{},"ISSN":["1170-229X","1179-1969"],"issn-type":[{"value":"1170-229X","type":"print"},{"value":"1179-1969","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,1,23]]}}}